Objective: To evaluate the efficacy of endorectal Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spetroscopic Imaging (MRSI) combined with total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) in selecting candidates for biopsy. Subjects and Methods: 246 patients with elevated tPSA (median: 7.81 ng/ml) underwent endorectal MRI and MRSI before Transrectal Ultrasound (TRUS) biopsy (10 peripheral + 2 central cores); patients with positive biopsies were treated with radical intention; those with negative biopsies were followed up and underwent MRSI before each additional biopsy if tPSA rose persistently. Mean follow-up: 27.6 months. We compared MRI, MRSI, tPSA, and fPSA with histopathology by sextant and determined the association between the Gleason score and MRI and MRSI. We determined the most accurate combination to detect prostate cancer (PCa) using receiver operating curves; we estimated the odds ratios (OR) and calculated sensitivity, specificity, and positive and negative predictive values. Results: No difference in tPSA was found between patients with and without PCa (p = 0.551). In the peripheral zone, the risk of PCa increased with MRSI grade; patients with high-grade MRSI had the greatest risk of PCa over time (OR = 328.6); the model including MRI, MRSI, tPSA, and fPSA was more accurate (Area under Curve: AUC = 95.7%) than MRI alone (AUC = 85.1%) or fPSA alone (AUC = 78.1%), but not than MRSI alone (94.5%). In the transitional zone, the model was less accurate (AUC = 84.4%). The association (p = 0.005) between MRSI and Gleason score was significant in both zones. Conclusions: MRSI is useful in patients with elevated tPSA. High-grade MRSI lesions call for repeated biopsies. Men with negative MRSI may forgo further biopsies because a significantly high Gleason lesion is very unlikely.
Introduction
The two most common methods of screening for prostate cancer (PCa), digital rectal examination (DRE) and serum total prostate-specific antigen (tPSA) levels, yield suboptimal accuracy. The specificity of tPSA is poor for levels < 10 ng/ml [1, 2] . Thus, 60% to 75% of men with tPSA between 4 ng/ml and 10 ng/ml undergo unnecessary biopsies [3] . Moreover, men can have elevated tPSA and multiple previous negative biopsies before a diagnosis of PCa is established. The use of %fPSA reduces the number of unnecessary biopsies whilst maintaining a high PCa detection rate [4, 5] . Combined endorectal MRI and 3D-MRSI have proven accurate in determining the location of PCa [6, 7] . We aimed to assess the value of endorectal MRI and 3D-MRSI combined with %fPSA to select patients for biopsy among men with elevated tPSA throughout long-term follow-up.
Material and Methods

Subjects
Our institutional review board approved this prospective study, and all patients provided informed consent.
We selected 246 patients (median age, 61.0 y; range, 44 -77) to undergo endorectal MRI/3D-MRSI before 12-core transrectal ultrasound-guided (TRUS) biopsy. Inclusion criteria were rise in tPSA > 50% or tPSA velocity > 0.75 ng/ml/year and negative or inconclusive DRE. No patients with clear nodules or hardness of the prostate at DRE were included. Before entering the study, 3 patients had undergone retropubic adenomectomy and 18 transurethral resection of the prostate (TURP) for symptoms of benign prostatic hyperplasia (BPH), so the transition zone was not biopsied in these 21 patients because of a lack of visible tissue at TRUS.
Patients with negative biopsies were followed-up, and they underwent MRI/3D-MRSI before each additional biopsy (up to 3) if tPSA rose persistently. Patients who were found prostate cancer were treated with radical treatment (Radical prostatectomy or Radiotherapy) if indicated. Variables collected included tPSA level and %fPSA.
MRI and 3D-MRSI Techniques
We used a 1.5-T whole-body MRI unit (Signa Horizon V.12.0; GE) with a body coil and a phased-array pelvic coil together with an expandable endorectal coil (Endo ATD Medrad; Warrendale, PA, USA) for signal recaption. We acquired A) axial T1-weighted sequences of the pelvic region and B) axial and coronal high resolution T2-weighted fast spin-echo sequences of the prostate and seminal vesicles. The 3D-MRSI data were processed and aligned with the corresponding MR image on a workstation using commercially available software (Functool, GE). Peak areas for choline, creatine, and citrate were calculated using numeric integration. Metabolic ratio maps of [choline + creatine]/citrate ([CC]/Ci) were generated.
The 3D-MRSI datasets were acquired as 16 × 8 × 8 phase-encoded spectral arrays (1024 voxels) with a spatial resolution of 0.24 -0.34 cm³ and 1000 130 . Image acquisition took 19 minutes and the entire examination, including coil placement, patient positioning, and MRI and 3D-MRSI acquisition took 50 to 60 minutes.
Image Interpretation
Three radiologists with extensive experience in MRI and 3D-MRSI imaging interpretation (12, 6 and 4 years experience, respectively) evaluated in consensus all MRI and MR spectroscopic findings. For tumor localization, the prostate was split along the midline and further divided into the apex, middle, and base of the gland (Figure 1) . Thus, the prostate was divided into 6 regions in the peripheral zone (PZ) and 2 in the transition zone (TZ). Image evaluation consisted of two parts. First, the three readers scored the T2-weighted images using a five-point scale. The presence of cancer, identified as an area of low signal intensity, was recorded for each region. Readers graded their confidence that cancer was present in each region on a five-point scale, as follows: grade 1 indicated definitely no tumor; 2, probably no tumor; 3, tumor possible; 4, tumor probable; and 5, tumor definitely present. Second, all 3D-MRSI data were read independently. All the voxels in the 8 regions were evaluated and each region was also scored on the five-point scale.
Mean values of the [CC]/Ci ratio were categorized using different scores for the PZ and TZ, according to Kurhanewicz et al. [8] . In the PZ, a score of 1 was assigned to voxels with [CC]/Ci<0.5; 2 to voxels with 0. 
Biopsy
After standard preparation, all patients underwent TRUS biopsy by using a US scanner (Allegra; Siemens, Erlangen, Germany) with a 6.5 MHz sector probe. Twelve prostatic cores were obtained using an 18-gauge biopsy needle (Bard Urological; Covington, GA, USA) with a spring-loaded biopsy gun (Manan Medical Pruducts, Northbrook, Ill.). In patients without pathological images on MRI/3D-MRSI, 10 cores were obtained from the PZ (Sextant biopsy + 4 lateral), and 2 from the TZ (one each side) (Figure 1 ). In patients with pathological images on MRI/3D-MRSI, additional cores were obtained from the site of the lesion. All cores were labeled according to their topographic location. The urologists responsible for carrying out the TRUS biopsy (JCB anb RBO) had extensive experience before this study.
When the biopsy after MRSI was negative, patients were followed up; if PSA kept rising and further biopsies were needed, patients underwent MRI/3D-MRSI before each biopsy. We performed a maximum of three biopsies if PCa was not found. 219 patients underwent a single biopsy after MRI/3D-MRSI, 17 patients underwent 2 biopsies, and 10 patients underwent 3 biopsies.
The material for histopathological evaluation consisted of biopsy cores, adenomectomy or TURP specimens from treatments performed during the study, and the whole gland in patients with PCa who underwent radical prostatectomy (RP).
Statistical Analysis
The PZ and TZ were analyzed separately. The maximum values of all readings for MRI and 3D-MRSI were taken for analysis in the PZ and in the TZ. We evaluated the four predictive variables (MRI, 3D-MRSI (5-point ordinal scales), tPSA, and %fPSA (continuous scales)) separately by fitting a binary logistic regression model with these variables as predictors. For MRI and 3D-MRSI, we considered 3 categories: MRI = 1 -2 (reference); MRI = 3; and MRI = 4 -5. Exceptionally, MRI was split into 2 categories [MRI = 1 -2 (reference) and MRI = 3 -5] in the statistical analysis of the TZ because few patients had MRI 4.
Two categories were considered for tPSA: 10 ng/ml (reference) and >10 ng/ml and two for fPSA: 15% (reference) and < 15%, according to Okamura et al. [9] .
We estimated the odds ratio (OR) of each category and its accuracy for predicting PCa from the area under receiver operating characteristic curves (AUC). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were also calculated. The OR of each category was compared with the OR = 1 of the reference category. The association between Gleason score and MRI/3D-MRSI scores was measured by Goodman and Kruskal's gamma coefficient (G). Gleason scores were grouped into three categories: up to Gleason 3 + 3; from 3 + 4 to 4 + 3; and from 3 + 5 to 5 + 5. We considered p-values < 0.05 significant.
Results
Median tPSA was 7.81 n/ml (range: 0.16 -71.00), and median fPSA was 13.08% (range: 0.12% -41.70%). Median follow-up was 22.4 months (range: 6 -81.3 months).
At the end of the study, 16 patients had undergone TURP or adenomectomy for BPH, 29 radical prostatectomy (RP), 25 radiation therapy (RT), and 5 hormone therapy (HT). PCa was detected in the PZ (areas 1 to 6) in 31.7% (78/246) patients and in the TZ (areas 7 -8) in 15.1% (34/225); 82.3% (28/34) of patients with cancer in the TZ also had cancer in the PZ.
Peripheral Zone
Mean tPSA in patients with PCa (9.63 ng/ml) was not statistically different than in patients without PCa (9.95 ng/ml) (p = 0.551). The estimated AUC of tPSA as a predictive variable was 0.708 (Table 1(A) and Figure 2) .
Mean %fPSA was lower in patients with PCa than in those without (12.4% vs. 15.0%; p < 0.001). The estimated AUC of %fPSA was 0.781 ( Table 1( (Table 2(A) ). The AUC of MRI was 0.851 (Figure 2) . The OR of MRI = 3 and MRI = 4 -5 were 7.9 and 57.4, respectively (Table 1(A) ).
In the analysis of 3D-MRSI, 95.1% (156 164 ) of patients with grade 1-2 lesions had negative biopsies and 95.3% (41/43) of patients with grade 4-5 3D-MRSI lesions had positive biopsies during follow-up (Table 2(A) ). Nevertheless, one of the two patients with grade 4-53D-MRSI lesions without cancer in the PZ had a positive biopsy (Gleason 6: 3 + 3) in the right TZ in the second set of biopsies. The second patient had a history of superficial bladder cancer treated with BCG 5 years before TRUS biopsy, which found granulomas suggestive of tuberculosis. The AUC of 3D-MRSI was 0.945 (Figure 2) . The OR of 3D-MRSI = 3 and 3D-MRSI = 4 -5 were 56.6 and 328.6, respectively (Table 1(A) ).
On the combined analysis of MRI-3D-MRSI, 100% (17/17) of patients with MRI = 4 -5 and 3D-MRSI = 4 -5 had PCa in the PZ. Four patients with PCa had MRI = 1 -2 and 3D-MRSI = 1 -2; they were found PCa in the third set of biopsies and all had a Gleason 6 (3 + 3) PCa in a single core at biopsy. The AUC of the model combining all variables (MRI, 3D-MRSI, tPSA, and fPSA) was 0.957 (Figure 2) , which is significantly greater than the AUC of MRI alone, tPSA alone, and fPSA alone, but not than the AUC of 3D-MRSI alone (Table 1(A) ). Table 1 (A) summarizes the sensitivity, specificity, and predictive values for all individual variables and for the multivariate model. Of the individual variables, 3D-MRSI had the highest sensitivity (89.7%), specificity (92.9%), PPV (85.4%), and NPV (95.1%). Combining all variables yielded higher sensitivity (91.0%), specificity (94.6%), PPV (88.8%), and NPV (95.8%) than 3D-MRSI alone, although differences were not statistically significant. (Table 2(B) ).
Transition Zone (TZ)
The AUC of MRI and 3D-MRSI were 0.758 and 0.813, respectively (Figure 3) . OR are summarized in Table 1 
(B).
The AUC of the model combining all variables was 0.844 (Figure 3) , which is significantly greater than the AUC of tPSA alone or %fPSA alone but not than the AUC of MRI alone or 3D-MRSI alone (Table 1(B) ).
The sensitivity (55.9%) and NPV (92.4%) of 3D-MRSI were similar to those of the other variables, but its specificity (95.3%) and PPV (67.9%) were significantly higher. The model combining all variables had a significantly higher sensitivity (76.5%) than MRSI alone, although its specificity (83.2%) and PPV (44.8%) were significantly lower. The NPV (95.2%) of the combined model was similar to that of 3D-MRSI alone (Table 1(B) ). 
Gleason versus MRI and 3D-MRSI
Discussion
Several studies have found benefits from using endorectal MRI and 3D-MRSI in diagnosing and staging PCa [7, 10] . In a meta-analysis of MRI and 3D-MRSI in the diagnosis of PCa, Umbehr et al. [11] concluded that although many studies had encouraging results [12] [13] [14] [15] [16] [17] [18] [19] [20] , larger studies were necessary to confirm its cost-effectiveness. They reported sensitivities and specificities from several studies ranging from 58% to 82% and from 78% to 91%, respectively, depending on the patient's risk for PCa. In the present study, we found a high sensitivity and specificity for MRI/3D-MRSI. Although MRI/3D-MRSI was more accurate in the PZ than in the TZ, the accuracy in the TZ is still good and is comparable to the accuracy reported for other series. This is probably related to the presence of experienced radiologists in specialized centers.
D'Amico et al. [21] reported the impact of including MRI in a multivariate analysis to predict extraprostatic cancer. MRI has also been advocated for planning surgery and deciding whether to resect the neurovascular bundle [22] . The European guidelines on PCa state that MRI could be accurate in staging PCa and that 3D-MRSI increases the accuracy of tumor localization and correlates with the Gleason score [23] . They also suggest using MRI/3D-MRSI in patients with previous negative biopsies with persistent clinical suspicion of PCa [24] , but the indications are still very vague regarding their use for early diagnosis of PCa.
The rationale behind evaluating the results according to the topographic location of PCa comes from the differences we observed in the accuracy for the detection of PCa depending on the site (TZ or PZ), and our goal was to evaluate the usefulness of MRI/3D-MRSI combined with clinical parameters in selecting candidates for biopsy according to the risk of having PCa, either in the PZ or the TZ. Thus, we focused on whether MRI/3D-MRSI is able to avoid biopsies in patients with elevated tPSA.
In the present study, tPSA ranged from 0.16 ng/ml in a patient with a previous adenomectomy with a microfocus of PCa in the pathologic specimen to 71.00 ng/ml in another with locally advanced PCa, but the median tPSA was relatively low (7.81 ng/ml); nevertheless, tPSA was not predictive of PCa. The model incorporating MRI, 3D-MRSI, and %fPSA was significantly more accurate in predicting PCa (AUC = 0.965) than other models using MRI alone (AUC = 0.857) or %fPSA alone (AUC = 0.640). In the TZ, the same model was less accurate (AUC = 0.845), but this result is still good, considering the heterogeneity of the TZ and the low detection rates of TRUS biopsy and TURP in the TZ [25, 26] .
Our study has two major limitations: First, is that biopsy results might not be a good representation of the real number of patients that have PCa; therefore, the sensitivity of MRI/3D-MRSI measured against this standard would lack validity. Nevertheless, this is a detection study, and the patients in our series were followed up from 6 months to several years, and at least 3 biopsies were performed to these patients if no cancer was found, to rule out PCa as far as possible. The second one is the limited correlation between MRI/3D-MRSI and TRUS, to ensure that cores were taken from the suspicious MRI area. For this reason, when performing the biopsies for this study, radiologists and urologists worked together to ensure as much as possible the best location of lesions detected at MRI/MRSI.
We confirm the relation between 3D-MRSI and Gleason score reported by Zakian et al. [27] , who suggested the potential of 3D-MRSI for noninvasive assessment of PCa aggressiveness.
We aimed to evaluate the predictive value of MRI/3D-MRSI in patients with suspected PCa and to correlate MRI/3D-MRSI findings with the clinical and pathological findings during long-term follow-up to establish the indication for MRI/3D-MRSI in these patients. We suggest patients with the following findings undergo TRUS biopsy: 1) Grade 4 or 5 3D-MRSI.
2) Grade 3 3D-MRSI and grade 3, 4, or 5 MRI. Finally, we are aware that multiparametric MRI has the advantages of being quicker and more widely available [28] than 3D-MRSI, which is time consuming and requires special software. However, MRI/3D-MRSI is cost-effective because it is less expensive and has similar accuracy to diffusion for PCa detection in the PZ and may be more accurate than multiparametric MRI in the TZ [29] . Thus, MRI/3D-MRSI remains a good tool for centers with experience.
Conclusions
1)
In patients with an elevated tPSA and fPSA < 15%, suspicious lesions at MRI/3D-MRSI must be biopsied. Negative biopsy results call for follow-up including repeat biopsies 2) In patients without suspicious lesions at 3D-MRSI, biopsies for high tPSA might be unnecessary.
3) Negative MRI/3D-MRSI findings suggest that significant PCa, either in volume or in grade, is unlikely; therefore, MRI/3D-MRSI may obviate subsequent biopsies in patients with high PSA or candidates for active surveillance.
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